Policy & Regulation

ndia Is Winning the China+1 Pharma War — Multinationals Are Pre-Qualifying Indian CMOs Right Now Because of BIOSECURE Act Policy Risk

By Mustafa Shariff, Editor in Chief · May 27, 2026 · 2 min read

Mustafa Shariff, Editor in Chief — ndia Is Winning the China+1 Pharma War — Multinationals Are Pre-Qualifying Indian CMOs Right Now Because of BIOSECURE Act Policy Risk

Summary

India's China+1 Pharma Moment: How the BIOSECURE Act Is Driving Global CMO Derisking Toward India
Multinational pharmaceutical companies are pre-qualifying Indian CMOs as BIOSECURE Act policy risk grows. Here is why this is India's most significant pharma CDMO opportunity in a generation.

"The BIOSECURE Act has not passed in its final form as of May 2026. But its policy intent has been clear, and its principal effect has already materialised: multinational pharmaceutical companies have begun pre-emptively qualifying alternative CMOs so that if the act does pass, they are not facing a regulatory manufacturing site change in the middle of a clinical trial."

The most consequential shift in global pharmaceutical manufacturing of 2026 may not involve a single drug approval, clinical trial outcome, or regulatory announcement. It involves the quiet, systematic qualification of Indian contract manufacturing organisations by global pharmaceutical companies seeking insurance against a specific policy risk: the potential restriction of WuXi AppTec and other Chinese pharmaceutical manufacturers under US national security legislation.

The BIOSECURE Act — US legislation that would restrict federal procurement from, and certain collaborations with, designated Chinese biotechnology companies including WuXi AppTec, BGI Genomics, and others on national security grounds — has not passed in its final legislative form as of May 2026. The Senate and House versions remain in reconciliation. But as DrugPatentWatch's comprehensive analysis of the India-China pharmaceutical rivalry documents: the act has not passed, but its policy intent has been clear, and its principal effect has already materialised. Multinational pharmaceutical companies have begun pre-emptively qualifying alternative CMOs so that if the act does pass, or if WuXi's operational access is restricted through executive action, they are not facing a regulatory manufacturing site change in the middle of a clinical trial.

Why Site Changes Are So Costly

The specific cost of being caught without an alternative CMO when a manufacturing restriction takes effect is severe and specific to pharmaceutical regulation. Manufacturing site changes for drug products require US FDA prior approval. The prior approval process typically takes 12 to 18 months. During that time, if the original manufacturing site is restricted or unavailable, the company faces a stark choice: stop supplying the drug (potentially causing patient access disruption) or seek expedited regulatory relief (which cannot be guaranteed). For a company with a clinical-stage asset manufactured at a WuXi facility, a site change requirement would delay clinical timelines by 12 to 18 months — an enormous cost in a competitive development environment where timeline is often the decisive factor in first-to-market advantage.

This specific risk has motivated pharmaceutical companies to begin the qualification process now, while the BIOSECURE Act remains pending, so that Indian manufacturing sites are regulatory-ready if and when restriction occurs. Qualification involves technology transfer to the new site, batch manufacturing to demonstrate process equivalence, analytical method validation, and regulatory filing preparation — a process that takes months but is far less disruptive than an emergency site change during active clinical development.

India's Position and Its Beneficiaries

India's pharmaceutical manufacturing ecosystem is uniquely positioned to capture this derisking demand. The country has the most US FDA-approved manufacturing facilities outside the United States — a regulatory track record that makes Indian CMO sites immediately credible as alternative qualification targets. India's CDMOs — Syngene International, Divi's Laboratories, Piramal Pharma Solutions, Laurus Labs, Aurigene (covered in BHC Media May 4 edition with its $100 million CRDMO investment), and a growing field of specialist manufacturers — have the technical capability, regulatory standing, and scale required to absorb significant CMO transfer volume.

The Operation Epic Fury disruption to the Middle East has added a second dimension to the supply chain derisking conversation: companies that had assumed geographic diversity in their supply chains have found that Strait of Hormuz dependency creates concentrated risk for specific raw material and API supply routes. India's position as both a manufacturing hub and a relatively Hormuz-independent logistics destination (with major port access via the Arabian Sea outside the Strait) reinforces its supply chain resilience argument.

The Broader Context: India vs China in Global Pharma

India's pharmaceutical competitive position against China operates on multiple fronts simultaneously. In the API market, India imports approximately 70% of its API requirements from China — creating dependency that Biopharma SHAKTI's bulk drug park investments are designed to reduce. In the CDMO market, India has a regulatory quality advantage over Chinese manufacturers in US and EU regulated markets. In the biosimilars market, India's established manufacturers are competing with Chinese biosimilar producers for global market share. And in the generic drugs market, the BIOSECURE Act-driven derisking conversation is creating new CDMO qualification demand that India's manufacturing ecosystem is well-positioned to serve.

BHC Perspective

At Bengaluru Health Community, the India-China pharmaceutical competition story directly affects Bengaluru's life sciences ecosystem. Syngene — a Bengaluru company — is one of India's most prominent potential beneficiaries of the BIOSECURE Act derisking conversation. For BHC founders building in pharmaceutical technology, CDMO services, or regulatory consulting — the qualification wave being triggered by BIOSECURE Act risk is a commercial opportunity arriving right now.

Frequently Asked Questions

Q: What is the BIOSECURE Act and what has been its effect on India?
A: US legislation targeting Chinese pharmaceutical manufacturers on national security grounds. Though not passed in final form as of May 2026, its policy signal has caused multinational pharmaceutical companies to pre-qualify Indian CMOs as alternatives, triggering a qualification wave toward Indian CDMOs like Syngene, Divi's, Piramal, Laurus, and Aurigene.

Q: Why are pharmaceutical companies pre-qualifying sites now rather than waiting?
A: FDA manufacturing site changes require 12-18 months for prior approval. Companies pre-qualifying Indian sites now ensure they have regulatory-ready alternatives if WuXi or other Chinese manufacturers are restricted — avoiding the catastrophic timeline cost of an emergency site change during active clinical development.

Q: Which Indian companies benefit from BIOSECURE Act derisking?
A: Syngene International (Bengaluru), Divi's Laboratories, Piramal Pharma Solutions, Laurus Labs, Aurigene (Dr Reddy's CRDMO arm), and a growing field of Indian CDMOs with FDA-approved facilities and established regulatory track records in US and EU markets.